Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II studyJavier Escaned, Adrian Banning, Justin E. Davies et al.|European Heart Journal|2017Cited by 295
Comparison of Zotarolimus- and Everolimus-Eluting Coronary StentsJavaid Iqbal, Stephan Windecker, Patrick W. Serruys et al.|Circulation Cardiovascular Interventions|2015Cited by 152
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trialAlexandra J. Lansky, Andreas Baumbach, William Wijns et al.|The Lancet|2018Cited by 61